Levels of IL-6 and TNF-α in diabetic rats: effect of quercetin
Flavonoids are widely used phenolic compounds in traditional medicine due to their health-beneficial features. Quercetin is a remarkable member of flavonols, which is a sub-family of flavonoids, with its broad biological activity. Using flavonoids as adjuvant agents in the treatment of diabetes mellitus is frequently being debated. Inflammation, which is mentioned in the
pathophysiology of diabetes, may be seen as a target for the adjuvant therapy. Thereby, in the present study, we aimed to investigate the effects of quercetin on the plasma inflammatory cytokines, namely interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in diabetic rats. Total six groups were assigned as controls and treatments (50 mg/kg and 100 mg/kg
quercetin) in diabetic and non-diabetic main groups. We found that diabetes resulted in a significant increase of plasma IL-6 and TNF-α levels (respectively p=0,01 and p=0,01). Both doses of quercetin reduced plasma IL-6 and TNF-α to the levels that in non-diabetic animals (respectively p=0,01 and p=0,01). In terms of inflammatory cytokine levels, there was no significance between non-diabetic quercetin injected and control animals (p=0,99). Therefore, we assumed that quercetin acts as an immunomodulator rather than an immunosuppressant in diabetic rats.
International Diabetes Federation. IDF Diabetes Atlas, 6th
ed.th ed. 2013 [cited 2014 Feb 12]. Available from URL:
Bending D, Zaccone P, Cooke A. Inflammation and type one
diabetes. International Immunology. 2012;24(6); 339–346.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and
treatment of type 2 diabetes: perspectives on the past,
present, and future. The Lance. 2014;383(9922); 1068–1083.
Cade WT. Diabetes-related microvascular and
macrovascular diseases in the physical therapy setting.
Physical Therapy. 2008;88(11); 1322–1335.
Gabay C. Interleukin-6 and chronic inflammation. Arthritis
Research & Therapy. 2006;8 Suppl 2; S3.
Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6
Induces Cellular Insulin Resistance in Hepatocytes. Diabetes.
Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces
insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and
tumor necrosis factor-alpha, overexpressed in human fat cells
from insulin-resistant subjects. The Journal of Biological
Chemistry. 2003;278(46); 45777–45784.
Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-
Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance
associated to obesity: the link TNF-alpha. Archives of
Physiology and Biochemistry. 2008;114(3); 183–194.
Kumar S, Pandey AK. Chemistry and biological activities of
flavonoids: an overview. The Scientific World Journal.
Formica JV, Regelson W. Review of the biology of
Quercetin and related bioflavonoids. Food and Chemical
Toxicology. 1995;33(12); 1061–1080.
Kelly GS. Quercetin. Monograph. Alternative Medicine
Review. 2011;16(2); 172–194.
Kanter M. Protective effects of thymoquinone on
streptozotocin-induced diabetic nephropathy. Journal of
Molecular Histology. 2009;40(2); 107–115.
Akash, Muhammad Sajid Hamid, Rehman K, Chen S. Role
of inflammatory mechanisms in pathogenesis of type 2
diabetes mellitus. Journal of Cellular Biochemistry.
King GL. The role of inflammatory cytokines in diabetes
and its complications. Journal of Periodontology. 2008;79(8
Bottino R, Lemarchand P, Trucco M, Giannoukakis N. Gene-
and cell-based therapeutics for type I diabetes mellitus.
Gene Therapy. 2003;10(10); 875–889.
Nicholas D, Odumosu O, Langridge, William H R.
Autoantigen based vaccines for type 1 diabetes. Discovery
Medicine. 2011;11(59); 293–301.
Phillips JM, Parish NM, Raine T, Bland C, Sawyer Y, De La
Peña, Hugo ve ark. Type 1 diabetes development requires
both CD4+ and CD8+ T cells and can be reversed by nondepleting
antibodies targeting both T cell populations. The
Review of Diabetic Studies 2009;6(2); 97–103.
Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM.
Beta cell MHC class I is a late requirement for diabetes.
Proceedings of the National Academy of Sciences.
Pinkse, Gabrielle G M, Tysma, Odette H M, Bergen, Cees A
M, Kester, Michel G D, Ossendorp F, van Veelen, Peter A ve
ark. Autoreactive CD8 T cells associated with beta cell
destruction in type 1 diabetes. Proceedings of the National
Academy of Sciences. 2005;102(51); 18425–18430.
Wedrychowicz A, Dziatkowiak H, Sztefko K. Interleukin-6
(IL-6) and IGF-IGFBP system in children and adolescents with
type 1 diabetes mellitus. Experimental and Clinical
Endocrinology & Diabetes. 2013;112(8); 435–439.
Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD,
Marcovina SM, D'Agostino, Ralph B Jr ve ark. Inflammatory
markers are increased in youth with type 1 diabetes: the
SEARCH Case-Control study. The Journal of Clinical
Endocrinology & Metabolism. 2010;95(6); 2868–2876.
Choi S, Choi K, Yoon I, Shin J, Kim J, Park W ve ark. IL-6
protects pancreatic islet beta cells from pro-inflammatory
cytokines-induced cell death and functional impairment in
vitro and in vivo. Transplant Immunology. 2004;13(1); 43–53.
Campbell IL, Hobbs MV, Dockter J, Oldstone MB, Allison J.
Islet inflammation and hyperplasia induced by the pancreatic
islet-specific overexpression of interleukin-6 in transgenic
mice. American Journal of Pathology. 1994;145(1); 157–166.
Wegner M, Araszkiewicz A, Piorunska-Stolzmann M,
Wierusz-Wysocka B, Zozulinska-Ziolkiewicz D. Association
Between IL-6 Concentration and Diabetes-Related Variables in
DM1 Patients with and without Microvascular Complications.
Inflammation. 2013;36(3); 723–728.
Lee L, Xu B, Michie SA, Beilhack GF, Warganich T, Turley S
ve ark. The role of TNF-alpha in the pathogenesis of type 1
diabetes in the nonobese diabetic mouse: analysis of dendritic
cell maturation. Proceedings of the National Academy of
Sciences. 2005;102(44); 15995–16000.
Koulmanda M, Bhasin M, Awdeh Z, Qipo A, Fan Z,
Hanidziar D ve ark. The role of TNF-α in mice with type 1- and
- diabetes. PLoS ONE. 2012;7(5); e33254.
Garber AJ. Obesity and type 2 diabetes: which patients are
at risk? Diabetes, Obesity and Metabolism. 2012;14(5); 399–
Yki-Järvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J,
Marjanen T ve ark. Effect of obesity on the response to insulin
therapy in noninsulin-dependent diabetes mellitus. The
Journal of Clinical Endocrinology & Metabolism. 1997;82(12);
Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP,
Gomes KB. The linkage between inflammation and Type 2
diabetes mellitus. Diabetes Research and Clinical Practice.
Zozulinska D, Wierusz-Wysocka B. Type 2 diabetes
mellitus as inflammatory disease. Diabetes Research and
Clinical Practice. 2006;74(2); S12.
Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M.
Quercetin ameliorates metabolic syndrome and improves the
inflammatory status in obese Zucker rats. Obesity. 2008;16(9);
Chuang C, Martinez K, Xie G, Kennedy A, Bumrungpert A,
Overman A ve ark. Quercetin is equally or more effective than
resveratrol in attenuating tumor necrosis factor- -mediated
inflammation and insulin resistance in primary human
adipocytes. American Journal of Clinical Nutrition. 2010;92(6);
Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L. Does
Quercetin Improve Cardiovascular Risk factors and
Inflammatory Biomarkers in Women with Type 2 Diabetes: A
Double-blind Randomized Controlled Clinical Trial.
International Journal of Preventive Medicine. 2013;4(7); 777–
Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U,
Plachta-Danielzik S ve ark. Quercetin reduces systolic blood
pressure and plasma oxidised low-density lipoprotein
concentrations in overweight subjects with a highcardiovascular
disease risk phenotype: a double-blinded,
placebo-controlled cross-over study. British Journal of
Nutrition. 2009;102(7); 1065–1074.
Manach C, Williamson G, Morand C, Scalbert A, Remesy C.
Bioavailability and bioefficacy of polyphenols in humans. I.
Review of 97 bioavailability studies. The American Journal of
Clinical Nutrition. 2005;81(1 Suppl); 230S-242S.
. 2011; 112 (6): 318-22.
Noyan T, Balahoroğlu R, Kömüroğlu U. The Effects of Vitamin
A, E, and C Combined Insulin Treatments on the
Antioxidant Enzymes in the Diabetic Rats. Türk Klinik Biyokimya
Derg. 2004; 2(3): 113-119.